Unknown

Dataset Information

Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer.


ABSTRACT:

Background

L'Hermitte's sign (LS) after chemoradiotherapy for head and neck cancer appears related to higher spinal cord doses. IMRT plans limit spinal cord dose, but the incidence of LS remains high.

Methods

One hundred seventeen patients treated with TomoTherapy™ between 2008 and 2015 prospectively completed a side-effect questionnaire (VoxTox Trial Registration: UK CRN ID 13716). Baseline patient and treatment data were collected. Radiotherapy plans were analysed; mean and maximum spinal cord dose and volumes receiving 10, 20, 30 and 40 Gy were recorded. Dose variation across the cord was examined. These data were included in a logistic regression model.

Results

Forty two patients (35.9%) reported LS symptoms. Concurrent weekly cisplatin did not increase LS risk (p

SUBMITTER: Laidley HM 

PROVIDER: S-EPMC5936022 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature